Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 22, 2026Clinical Cancer Research

Abstract PS2-07-23: Predictive markers of distant recurrence from randomized chemotherapy regimens for hormone receptor-positive breast cancer patient in the PACS-01 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

FPF. PENAULT-LLORCAALA. LusqueTFT. FILLERON

Discussion

Loading...

Member takes

Overview

This analysis demonstrates the predictive value of the SETER/PR index for distant recurrence in hormone receptor-positive breast cancer, highlighting implications for treatment choices.

Key Points

  • The study aimed to assess if the SETER/PR index can predict the benefits of adding docetaxel to anthracycline-based chemotherapy in HR+ breast cancer patients.
  • Evaluated tumor samples for SETER/PR index using a QuantiGene assay.
  • Conducted a comparative analysis of two chemotherapy regimens in randomized patients.
  • Used a multivariable Cox proportional hazards model to test interactions between biomarkers and treatment effects.
  • Significant interaction observed between continuous SETER/PR index and chemotherapy on distant recurrence-free interval (Pinteraction = 0.028).
  • Optimal predictive cut point for SETER/PR index was identified at 1.50; higher values favored 6FEC (HR 3.16).
  • No predictive value found for recurrence score between chemotherapy regimens.

Cite This Study

PENAULT-LLORCA et al. (2026) studied this question.

synapsesocial.com/papers/699a9dcd482488d673cd3eeahttps://doi.org/10.1158/1557-3265.sabcs25-ps2-07-23
View Full Paper
Ask AI
Bookmark
Share